Balachandran Madhavan sold $526K of QURE

Balachandran Madhavan sold 11,685 shares of uniQure N.V. (QURE) at an average of $45.06 ($42.60–$47.08, $0.53M total) across 3 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Balachandran Madhavan
Published Jun 22, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The disclosed open-market sale totals $526,484.60 across three trades on 2026-06-17, with a stated 10b5-1 pre-arranged plan.

02

Market read

This provides a fresh datapoint on insider activity, but it does not introduce new fundamentals or catalysts for QURE.

03

What to watch

Traders may over-weight insider sales; without concurrent news (trial results, guidance, financing), the signal is usually weak and should be treated as sentiment noise.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-06-22)

Background

The article is a newly filed SEC Form 4 insider transaction for uniQure N.V. (QURE) by director Balachandran Madhavan.

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure director Balachandran Madhavan sold $526,484 of QURE shares via an open-market sale under a 10b5-1 plan on 2026-06-17.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental implication from this Form 4 alone.

Evidence & confidence

The filing is a routine Form 4 insider transaction with disclosed trade size, dates, and 10b5-1 pre-arrangement, without any accompanying operational or guidance change.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical catalyst mentioned.

None indicated; no cross-border deal, listing, or macro linkage described.

None indicated; no global partnership, trial, or financing event disclosed.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction; director Balachandran Madhavan sold shares.

  • Balachandran Madhavan

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.